Nykode Therapeutics ASA

NYKD · Oslo Børs · Healthcare

3.48NOK +0.7%last day

Price as of 2 October 2026

The price over the past year, with dividends: +105.6%

Performance

1 month

−14.8%

1 year

+105.6%

3 years, per year

−40.6%

5 years, per year

−39.8%

Largest fall, 3 years

−97.4%

Below the peak now

−94.2%

Volatility, 1 year

92.5%

Return with dividends reinvested.

Key figures

P/E

negative earnings

P/B

1.5

Dividend yield

0.0%

Return on equity

−70.0%

Net margin

−63.6%

Market value

118 m USD

Quality, value and trend

Where Nykode Therapeutics stands against every Nordic stock today. 100 is best.

Quality36

Profitability and a sound balance sheet over time. Better than 36% of Nordic stocks.

Value10

The price measured against earnings, assets and cash flow. Better than 10% of Nordic stocks.

Trend86

The price development over the past year. Better than 86% of Nordic stocks.

Combined36

Quality, value and trend together. Better than 36% of Nordic stocks.

About Nykode Therapeutics

Nykode Therapeutics ASA is a company in healthcare, listed on Oslo Børs. The share trades in NOK. It has around 59 employees.

Nykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies for the treatment of cancer and autoimmune diseases. The company develops vaccines for the treatment cancer, autoimmune, and infectious diseases. Its lead product candidates include ABI-SUVA for targeting HPV16+ induced malignancies, with head, and neck cancer as the primary indication is in Phase 2 randomized controlled trial. It also offers VB10.NEO, which is in Phase1b VB-N-02 trial; technology platform, which combines genes with desired properties to make novel compounds by creating a new code. Nykode Therapeutics AS was founded in 2006 and is headquartered in Oslo, Norway.

See the full analysis in InvestWiser.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

See the full analysis